NCT07290283 A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
| NCT ID | NCT07290283 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | AstraZeneca |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 176 participants |
| Start Date | 2025-12-10 |
| Primary Completion | 2026-10-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 176 participants in total. It began in 2025-12-10 with a primary completion date of 2026-10-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
Eligibility Criteria
Inclusion Criteria: * Healthy male and female (of non-childbearing potential) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit. * All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via post-menopausal status or documentation of irreversible surgical sterilization at the Screening Visit. * Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods. * Have a body mass index between 18 and 32 kg/m2 inclusive and weigh at least 50 kg at Screening. * For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female participants are to be Japanese (eg, natives of Japan or Japan Americans), defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan. * For healthy Chinese cohort (Part A3): healthy male and female Chinese participants for whom both parents and 4 grandparents are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China. Exclusion Criteria: * History of any clinically important disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * Any abnormal laboratory values, vital signs, or any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results. * Any positive result on Screening for serum hepatitis B and C viruses and human immunodeficiency virus. * Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiography at Screening and/or admission to the Clinical Unit . * Known or suspected history of alcohol or drug abuse or excessive intake of alcohol. * Positive screen for drugs of abuse, or alcohol, or cotinine. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity. * Participants who have previously received AZD3974.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07290283 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07290283 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07290283 currently recruiting?
Yes, NCT07290283 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07290283 trial being conducted?
This trial is being conducted at Glendale, United States, Baltimore, United States.
Who is sponsoring the NCT07290283 clinical trial?
NCT07290283 is sponsored by AstraZeneca. The trial plans to enroll 176 participants.